Cancer treatment modalities
AssigneeEpizyme, Inc.
InventorScott RIBICH
Life of this patent
Estimating the term…
Abstract
The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer. Some aspects of this disclosure provide treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers, dependent upon EZH2 (enhancer of zeste 2 polycomb repressive complex 2) function with an EZH2 inhibitor.
Claims27
A method, comprising administering an enhancer of a zeste homolog 2 (EZH2) inhibitor to a subject having or diagnosed with a cell proliferative disorder characterized by a cell or a population of cells that exhibits a loss of function of SMARCA2 and/or SMARCA4.
A method of treating a cell proliferative disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor, wherein the cell proliferative disorder is characterized by a cell or a population of cells that exhibits a loss of function of SMARCA2 and/or SMARCA4.
(canceled)
A method of treating a cell proliferative disorder of the lung in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor.
-21. (canceled)
-26. (canceled)
-32. (canceled)
(canceled)
-42. (canceled)
-105. (canceled)
Dependencies are inferred from the claim text.